Portfolio Building Block World Pharma and Biotech Index ETF
$27.93−0.48 (−1.68%)
- 0.13%
- $1.0B
- 0.1M sh
- $28.28
- low $24.18high $29.90
The ETF.net PBPH Grade
B
Score 62 out of 100
- 5 of 9
Score 62 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.A94 out of 100Rank 1 of 9Mission
Whether the fund did what it promised, tested against its stated mandate.Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.C49 out of 100Rank 5 of 9Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.D34 out of 100Rank 6 of 9Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.D35 out of 100Rank 8 of 9Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.C49 out of 100Rank 6 of 9
Our read on PBPH
BMost biotech funds stop at the US border. PBPH buys the developed world's drug complex, pharma and biotech together, through a plain index fund charging 0.13%.
The Fund seeks to track, before fees and expenses, the performance of the BITA Global Pharma and Biotech Select Index.
Why people hold it
- 0.13% a year, in a global thematic aisle where the typical fund charges several times that. Fee drag is about as small as this shelf gets.
- Pharma and biotech under one ticker, global rather than US-only, so overseas drugmakers sit alongside the American names.portfoliobuildingblocketfs.com
- Straight index replication inside an ordinary 1940 Act fund. Published rules do the picking, not a manager's hunch.
- Cheap build plus workable trading puts it among the stronger implementations in its global thematic peer group.
Worth knowing
- One industry, one storyline. Drug pricing rules, patent cliffs and trial readouts swing this basket in ways the broad market does not feel.
- Launched in late 2025, so there is no long live record showing how closely it hugs the index across a full cycle.
- Cash comes back once or twice a year, not monthly. This is an exposure holding, not an income schedule.
PBPH Holdings
- Stocks
- 54
- 64%
- LLY.TO
Geography
- United States75.24%
- Switzerland5.62%
- United Kingdom5.59%
- Japan4.17%
- France2.06%
- Germany1.65%
- Australia1.46%
- Netherlands1.22%
- 2.98%
Developed 94% · Emerging 6%
PBPH Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Not enough history yet.Not enough history yet.Not enough history yet.Not enough history yet.
PBPH$11,253
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | PBPH |
|---|---|
| Year to date | +12.5% |
| 1 month | +2.2% |
| 3 months | +4.8% |
| 1 year | — |
| 3 years | — |
| 5 years | — |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | PBPH |
|---|---|---|
| 2026 YTD | +12.5% | |
| 2025 | +0.7% |
PBPH in the news
PBPH Dividends
- $0.02 per share
- Irregular
Distribution data unavailable.
Distribution history
PBPH Risk
- —
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- —
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- —
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.05
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
PBPH Cost
0.13%
PBPH0.13%
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
No Pharma & Therapeutics fund charges less.
Other funds in Pharma & Therapeutics
- BXPHState Street SPDR S&P Pharmaceuticals ETFExpense ratio 0.35%1 year return +35.9%
- BPJPInvesco Pharmaceuticals ETFExpense ratio 0.58%1 year return +34.5%
- BFTXHFirst Trust Nasdaq Pharmaceuticals ETFExpense ratio 0.60%1 year return +43.8%
- COZEMRoundhill Investments - GLP-1 & Weight Loss ETFExpense ratio 0.59%1 year return +3.7%
- CTHNRAmplify Weight Loss Drug & Treatment ETFExpense ratio 0.59%1 year return +4.1%